Mair Therapeutics

What Mair Therapeutics does

Mair Therapeutics B.V. is a Dutch preclinical biotechnology company founded in February 2025 and headquartered in Nijmegen, Netherlands. The company develops small-molecule drug candidates that act as agonists of TMEM175, a lysosomal proton leak channel that is genetically linked to Parkinson's disease. Its core product is a portfolio of TMEM175-targeting compounds designed to restore lysosomal degradation capacity, clear toxic protein aggregates such as alpha-synuclein, and protect dopaminergic neurons from degeneration. The platform is described as AI-powered, leveraging computational drug discovery to identify compounds that enhance TMEM175 activity, and is positioned as a disease-modifying approach addressing the underlying lysosomal dysfunction rather than the symptomatic features of Parkinson's disease.

Mair is led by CEO Dr. Vasily Kazey (PhD in neuroscience, Venture Partner at Torrey Pines Investment) and VP of Medicinal Chemistry Dr. Alexei Pushechnikov (PhD in Element-Organic Chemistry), and operates with 1-10 employees. The company is pre-revenue and pre-seed-funded by Torrey Pines Investment and Oost NL, the latter anchoring Mair within the East Netherlands neuroscience and innovation ecosystem. In January 2026, Mair entered a scientific collaboration with Radboud University's Donders Centre for Neuroscience (Kuijpers Lab) to evaluate its compounds in human neuron models derived from Parkinson's patients and healthy donors.

Mair's business model is built around preclinical validation of TMEM175 agonists followed by out-licensing, co-development partnerships, or acquisition by larger pharmaceutical companies once clinical efficacy is demonstrated; no such transactions have been disclosed. The company's go-to-market relies on scientific publications, academic partnerships, and conference visibility rather than direct sales, consistent with the standard playbook for early-stage CNS biotechs pursuing an exit via pharma partnership.

Name

Mair Therapeutics

Legal name

Mair Therapeutics B.V.

Website

https://mairtx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Mair Therapeutics is a Netherlands-based preclinical biotechnology company developing small-molecule TMEM175 agonists to restore lysosomal function and halt Parkinson's disease progression, using an AI-powered drug discovery platform targeting genetically validated disease mechanisms.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)

Keywords

• Parkinson's disease therapeutics
• Small molecule drug discovery
• Neurodegenerative disease research
• Lysosomal function modulators
• TMEM175 ion channel agonists

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Therapeutic Development & Licensing: Pre-revenue biotech company. As a drug development venture, revenue would be generated through licensing deals, co-development partnerships, or acquisition by pharmaceutical companies after demonstrating clinical efficacy of TMEM175-targeted therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Mair Therapeutics is a clinical-stage biotechnology company developing small-molecule TMEM175 agonists intended to restore lysosomal function in dopaminergic neurons and halt or slow the progression of Parkinson's disease. The company's AI-powered drug discovery platform identifies compounds that enhance TMEM175 activity to clear toxic protein aggregates such as alpha-synuclein, addressing the root cellular cause of neurodegeneration rather than symptoms. Compounds are currently being evaluated in human neuron models through academic collaborations ahead of any clinical development.

Product overview

Mair Therapeutics is a biotechnology company developing a single therapeutic pipeline focused on small-molecule TMEM175 agonists for Parkinson's disease. The company's drug discovery platform identifies compounds that enhance TMEM175 activity to restore lysosomal degradation capacity, protecting dopaminergic neurons from toxic protein aggregation.

Differentiator

Problem solved

Functional benefit

Products and services

• TMEM175 Agonists

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Radboud University (Donders Centre for Neuroscience)coreStrategic or Co-development Partner · 26 January 2026Mair Therapeutics entered a scientific collaboration with Radboud University's Donders Centre for Neuroscience, led by Dr. Marijn Kuijpers, to evaluate the company's TMEM175-targeting compounds in human neuron models derived from Parkinson's disease patients and healthy donor cells. The partnership focuses on assessing lysosomal pH regulation and degradation capacity to determine whether enhancing TMEM175 activity could restore cellular cleanup functions and protect vulnerable neurons.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Prothena Corporation: Late-stage biotech developing therapies targeting alpha-synuclein and other protein aggregation pathways implicated in Parkinson's disease. Directly comparable as both companies pursue disease-modifying Parkinson's therapies addressing protein misfolding and aggregation.
• Prevail Therapeutics (a wholly owned subsidiary of Eli Lilly): Gene therapy company developing treatments for Parkinson's disease and other neurodegenerative disorders, acquired by Eli Lilly. Directly comparable given the shared focus on lysosomal biology and Parkinson's disease drug development.
• Denali Therapeutics: Clinical-stage biotech developing small-molecule therapeutics targeting lysosomal function and neurodegeneration, including Parkinson's disease programs. Directly comparable to Mair given the shared focus on lysosomal biology and CNS drug discovery.
• Voyager Therapeutics: Clinical-stage gene therapy company with Parkinson's disease programs targeting neurodegenerative mechanisms. Comparable as a neuroscience-focused biotech pursuing disease-modifying Parkinson's approaches, though Mair is focused on small molecules rather than gene therapy.

Broad incumbents

• Exscientia: AI-driven drug discovery company with partnerships across multiple therapeutic areas including CNS. Comparable to Mair given the shared AI-first drug discovery platform approach and focus on small-molecule design.
• Recursion Pharmaceuticals: Clinical-stage TechBio company combining AI, high-throughput biology, and chemistry for drug discovery across multiple therapeutic areas including neurodegeneration. Comparable to Mair given the AI-driven drug discovery platform approach.
• Cerevel Therapeutics (acquired by AbbVie): Clinical-stage neuroscience company developing small-molecule therapies for Parkinson's disease and other CNS disorders, recently acquired by AbbVie for $8.7B. Comparable as a neuroscience-focused biotech pursuing small-molecule Parkinson's therapies at larger scale.

Emerging players

• Aspen Neuroscience: Clinical-stage company developing autologous cell replacement therapies for Parkinson's disease. Comparable as a focused Parkinson's therapeutics company pursuing disease-modifying approaches, though Mair's small-molecule strategy differs from cell therapy.
• Alterity Therapeutics: Clinical-stage biotechnology company developing therapies for neurodegenerative diseases including Parkinson's disease, targeting protein aggregation and iron dysregulation. Comparable as a small, focused neurodegenerative disease biotech pursuing disease-modifying approaches.
• BioXcel Therapeutics: Clinical-stage biopharmaceutical company leveraging AI-driven drug discovery for neuroscience and immuno-oncology applications. Comparable to Mair given the shared use of AI for drug discovery in CNS indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/mair-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mair Therapeutics